Last updated January 19th 2017
January 3, 2017 | Israeli flu vaccine developer BiondVax Pharmaceuticals Ltd. has announced that Angels High Tech Investments Ltd. has agreed to invest NIS 10.9 million (approximately $2.83 million) in the company in exchange for 33.8 million ordinary BiondVax shares on the Tel Aviv Stock Exchange (equivalent to 844,000 Nasadq listed ADS) at the December 29, 2016 Tel Aviv closing market price. Following the transaction, Angels Investments will hold 19.99% of all issued and outstanding share capital of BiondVax. Angels High Tech Investments is a company fully owned by Marius Nacht, co-founder and chairman of Check Point Software Technologies Ltd.. Angels High Tech Investments’ healthcare and life science portfolio is managed by aMoon Partners which is co-led by Dr. Yair Schindel and Marius Nacht. BiondVax is a clinical phase biopharmaceutical company developing a universal flu vaccine. The vaccine is designed to provide multi-season protection against most seasonal and pandemic human influenza virus strains. BiondVax’s proprietary technology utilizes a unique combination of conserved and common peptides from influenza virus proteins, activating both arms of the immune system for a cross-protecting and long-lasting effect.